Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

8.870 +0.160 (+1.84%)
Official Closing Price Updated: 4:10 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Gap Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers Oncorus, Inc. (NASDAQ: ONCR) shares rose 90% to $0.38 in pre-market trading after dropping around 17% on Thursday. Oncorus recently posted a narrower-than-expected quarterly loss. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for another dive into the biggest pre-market stock movers as we check out what's happening this morning on Friday! 
Via InvestorPlace
Earnings Preview For Arcus Biosciences
Via Benzinga
Arcus Biosciences Earnings Perspective: Return On Capital Employed
Via Benzinga
Where Arcus Biosciences Stands With Analysts
Via Benzinga
Expert Ratings for Arcus Biosciences
Via Benzinga
Arcus Biosciences Return On Capital Employed Insights
  
Via Benzinga
3 Analyst Upgrades That Smart Investors Won’t Ignore
In many cases, analyst upgrades can point investors to opportunities like the ones in the stocks on this list. 
Via InvestorPlace
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Recap: Arcus Biosciences Q2 Earnings
Arcus Biosciences (NYSE:RCUS) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:03 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall. 
Via Investor's Business Daily
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
The market uptrend is under pressure. 
Via Investor's Business Daily
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
Dow Jumps 150 Points; Crude Oil Rises 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who... 
Via Benzinga
Nasdaq Edges Lower; Gold Rises 1.5%
U.S. stocks traded mixed midway through trading, with the S&P 500 and the Nasdaq Composite moving lower on Tuesday. 
Via Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
US Stocks Edge Higher; Dow Rises 50 Points
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 50 points on Tuesday. 
Via Benzinga
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients
Via Benzinga
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
Via Benzinga
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
ON Semiconductor, Global Payments And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Arcus Biosciences
Over the past 3 months, 4 analysts have published their opinion on Arcus Biosciences (NYSE:RCUS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.